Gerresheimer (GXI) Q3 2025 earnings summary

Executive summary

• Q3 and 9M 2025 results were below expectations, with organic revenues down 1.8% and adjusted EBITDA down 7.5% year-over-year, despite reported revenue growth from the Bormioli Pharma acquisition.

• Net income for 9M 2025 declined to -€12.1m, impacted by exceptional items and restructuring, while adjusted EPS dropped to €2.05.

• Leadership changes included a new CFO, new Executive Board member, and new business unit heads to drive transformation.

• A comprehensive transformation program and Transformation Office were launched to improve performance, margins, and cash flow.

• Capital structure flexibility increased by repaying €200m of bridge loan and resetting covenants.

Financial highlights

• Q3 2025 revenues were €561m, up 12.5% year-over-year, with organic growth at -1.8%; adjusted EBITDA was €117m, down 9.4% organically.

• 9M 2025 revenues reached €1,728m, up 14.6% reported, with organic growth at -1.8%; adjusted EBITDA was €341m, down 7.5% organically.

• Adjusted EBITDA margin declined to 18.8% in Q3 and 18.7% for 9M 2025.

• Free cash flow before M&A improved to €21m in Q3 2025.

• Net financial debt rose to €2,015.9m as of Q3 2025, with leverage at 4.15x.

Outlook and guidance

• FY 2025 organic revenue is expected to decline by 2% to 4%, with adjusted EBITDA margin guided at 18.5%–19%.

• Adjusted EPS is projected to decrease by a mid to low double-digit percentage.

• Q4 2025 is expected to be stronger than Q3, but not enough to offset the weak first nine months.

• Transformation initiatives are underway to recover margins and return to profitable growth.